Buprenorphine Screen, Random, Urine
Use
Screening for drug abuse or use of buprenorphine. This assay provides a preliminary analytical test result and must be confirmed by a more specific method such as liquid chromatography tandem mass spectrometry when a positive screening result occurs. It is useful in clinical monitoring and management but not intended for employment‐related or forensic testing. Buprenorphine is a partial mu-opioid receptor agonist with reduced clinical effects and prolonged duration; it is metabolized via N-dealkylation to norbuprenorphine, which is active but less potent, and then glucuronidated to inactive forms.
Special Instructions
Not provided.
Limitations
As with all immunoassays, false-positive results may occur due to cross-reactivity with substances other than the intended analyte, and false-negative results may occur depending on antibody specificity. Urine dilution, fluid intake, and other biologic factors can influence results. Less than the required 5 mL specimen will compromise the ability to perform necessary testing.
New York Approved
Methodology
Immunoassay
Biomarkers
Buprenorphine
Protein
LOINC Codes
- 93494-3 - Buprenorphine Ur Ql Scn
- 93494-3 - Buprenorphine Ur Ql Scn
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
5 mL
Minimum Volume
Not provided
Container
Plastic urine container (submit in plastic vial); supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Instructions
Collect a random urine specimen; submit 5 mL in one plastic vial; no preservative.
Causes for Rejection
Submitting less than 5 mL will compromise the ability to perform all necessary testing.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 14 days |